A. Robidoux

发表

Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.

D. Wickerham, N. Wolmark, E. Mamounas, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.

Anna L. Brown, J. Bryant, D. Wickerham, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

C K Redmond, B Fisher, C. Redmond, 1999, Journal of the National Cancer Institute.

Risk of Breast Cancer Among French‐Canadian Women, Noncarriers of More Frequent BRCA1/2 Mutations and Consumption of Total Energy, Coffee, and Alcohol

A. Robidoux, S. Narod, B. Shatenstein, 2009, The breast journal.

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.

S. Paik, C. Geyer, N. Wolmark, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial.

T. Julian, J. Costantino, N. Wolmark, 2007, The Lancet. Oncology.

Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial.

T. Julian, J. Costantino, N. Wolmark, 2010, The Lancet. Oncology.

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.

H. Mackay, A. Oza, D. Huntsman, 2011, The Lancet. Oncology.

Multifocal, Nascent, and Invasive Myoepithelial Carcinoma (Malignant Myoepithelioma) of the Breast: An Immunohistochemical and Ultrastructural Study

L. Gaboury, A. Robidoux, G. Gabbiani, 2002, International journal of surgical pathology.

Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.

B Fisher, J Costantino, C. Redmond, 1996, Journal of the National Cancer Institute.

Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer

A. Robidoux, E. Bareke, N. Alirezaie, 2020, Scientific Reports.

Progress on BIG 1-02/IBCSG 27-02/NSABP B-37, a Prospective Randomized Trial Evaluating Chemotherapy after Local Therapy for Isolated Locoregional Recurrences of Breast Cancer

N. Wolmark, E. Mamounas, A. Robidoux, 2008, Annals of Surgical Oncology.

Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer.

G. Pond, D. Coyle, A. Robidoux, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes. The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial

S. Reis, W. McCaskill-Stevens, S. Lippman, 2006 .

Diet, lifestyle and BRCA-related breast cancer risk among French-Canadians

A. Robidoux, S. Narod, P. Ghadirian, 2006, Breast Cancer Research and Treatment.

Weight History, Smoking, Physical Activity and Breast Cancer Risk among French-Canadian Women Non-Carriers of More Frequent BRCA1/2 Mutations

A. Robidoux, S. Narod, B. Shatenstein, 2009, Journal of cancer epidemiology.

Axillary Lymph Node Ultrasound Following Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: Results from the SN FNAC Study

L. Gaboury, A. Robidoux, M. Basik, 2019, Annals of Surgical Oncology.

Abstract S3-02: NSABP B-36: A randomized phase III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC) in patients (pts) with node-negative breast cancer

T. Julian, C. Geyer, D. Wickerham, 2015 .

Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer.

A. Oza, D. Huntsman, K. Swenerton, 2010 .

Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.

S. Paik, G. Tang, J. Costantino, 2015, The Lancet. Oncology.

Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.

M. Buyse, C. Geyer, N. Wolmark, 2011, Clinical breast cancer.

Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial

R. Gelber, C. Geyer, N. Wolmark, 2017, Annals of Surgical Oncology.

Abstract PD2-1: The effect on overall and disease-free survival (OS & DFS) by adding bevacizumab and/or antimetabolites to standard neoadjuvant chemotherapy: NSABP Protocol B-40

S. Paik, G. Tang, J. Costantino, 2015 .

Technetium-99 m-- Sestamibi Prone Scintimammography to Detect Primary Breast Cancer and Axillary Lymph Node Involvement

A. Robidoux, R. Lambert, S. Turpin, 2006 .

Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.

S. Paik, G. Tang, J. Costantino, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Systemic therapy in patients with node-negative breast cancer. A commentary based on two National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trials.

C. Redmond, D. Wickerham, N. Wolmark, 1989, Annals of internal medicine.

Comparative Evaluation of Iodine-125 Radioactive Seed Localization and Wire Localization for Resection of Breast Lesions

A. Robidoux, M. Labelle, I. Trop, 2017, Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes.

Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study

T. Julian, C. Geyer, N. Wolmark, 2014, Breast Cancer Research and Treatment.

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).

M. Lux, R. Greil, A. Schneeweiss, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy?

O. Olopade, W. Foulkes, K. Offit, 2013, Breast Cancer Research and Treatment.

Impact of the 21-Gene Recurrence Score Assay on Treatment Decisions and Cost in Patients with Node-Positive Breast Cancer: A Multicenter Study in Quebec

A. Robidoux, M. Guertin, L. Sidéris, 2022, The oncologist.

Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)

T. Julian, C. Geyer, P. Ward, 2021, Breast Cancer Research and Treatment.

Randomized phase II placebo-controlled trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone receptor-positive metastatic breast cancer (MBC): OCOG Zamboney study—NCT00811369.

G. Pond, A. Robidoux, S. Chia, 2013 .

Abstract S3-2: Chemotherapy prolongs survival for isolated local or regional recurrence of breast cancer: The CALOR trial (Chemotherapy as Adjuvant for Locally Recurrent breast cancer; IBCSG 27-02, NSABP B-37, BIG 1-02)

R. Gelber, N. Wolmark, J. Nortier, 2012 .

Final updated results of the NRG Oncology/NSABP Protocol P-2: Study of Tamoxifen and Raloxifene (STAR) in preventing breast cancer.

S. Reis, W. McCaskill-Stevens, L. Ford, 2015 .

Screening for BRCA1 and BRCA2 mutations among French‐Canadian breast cancer cases attending an outpatient clinic in Montreal

A. Robidoux, S. Narod, P. Ghadirian, 2014, Clinical genetics.

The LISA randomized trial of a weight loss intervention in postmenopausal breast cancer

G. Pond, J. Gralow, A. Robidoux, 2020, npj Breast Cancer.

Haplotype Analysis of BRCA2 8765delAG Mutation Carriers in French Canadian and Yemenite Jewish Hereditary Breast Cancer Families

A. Mes-Masson, W. Foulkes, D. Provencher, 2001, Human Heredity.

Breast cancer risk in relation to the joint effect of BRCA mutations and diet diversity

A. Robidoux, S. Narod, P. Ghadirian, 2009, Breast Cancer Research and Treatment.

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

Norman Wolmark, Scott M Lippman, S. Reis, 2006, JAMA.

Abstract P3-12-01: Impact of treatment on quality of life (QOL) and menstrual history (MH) in the NSABP B-36: A randomized phase III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide

E. Perez, N. Wolmark, P. Ward, 2015 .

Randomized trial of a telephone-based weight loss intervention in postmenopausal women with breast cancer receiving letrozole: the LISA trial.

G. Pond, J. Gralow, A. Robidoux, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Can MRI accurately identify which patients with operable breast cancer will have a pathologic complete response after neoadjuvant therapy

E. Mamounas, A. Robidoux, I. Trop, 2012 .

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer

Joseph P. Costantino, V. Craig Jordan, Victor G. Vogel, 2010, Cancer Prevention Research.

Total Synthesis of the Proposed Structure of Rhodobacter sphaeroides Lipid A Resulting in the Synthesis of New Potent Lipopolysaccharide Antagonists

A. Robidoux, W. Christ, Y. Wang, 1994 .

E5531, a pure endotoxin antagonist of high potency.

A. Robidoux, W. Christ, M. Perez, 1995, Science.

Actinomycin‐D plus 5‐(3,3‐dimethyl‐ 1‐triazeno)‐ imidazole‐4‐carboxamine (DTIC) with or without intravenous corynebacterium parvum in metastatic malignant melanoma

A. Robidoux, E. Hersh, J. Gutterman, 1982, Cancer.

Using the 21‐gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial

H. Bear, A. Robidoux, Angel A. Rodriguez, 2017, Journal of surgical oncology.

NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2.

S. Paik, J. Costantino, C. Geyer, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Germline RAP80 mutations and susceptibility to breast cancer

A. Robidoux, S. Narod, H. Lynch, 2008, Breast Cancer Research and Treatment.

Identification of a novel CHEK2 variant and assessment of its contribution to the risk of breast cancer in French Canadian women

W. Foulkes, P. Tonin, Longlong Chen, 2008, BMC Cancer.

The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study

Stephanie A Cohen, F. Couch, O. Olopade, 2016, British Journal of Cancer.

Frequency of the CHEK2 1100delC mutation among women with breast cancer: an international study.

D. Horsman, W. Foulkes, Z. Aziz, 2008, Cancer research.

A Unique Morphological Phenotype in Chemoresistant Triple-Negative Breast Cancer Reveals Metabolic Reprogramming and PLIN4 Expression as a Molecular Vulnerability

P. Tonellato, C. Borchers, A. Robidoux, 2019, Molecular Cancer Research.

Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.

S. Paik, G. Tang, J. Costantino, 2013, The Lancet. Oncology.

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.

L. Ford, J. Costantino, D. Wickerham, 2005, Journal of the National Cancer Institute.

Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study.

M. Brackstone, L. Gaboury, A. Robidoux, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

Norman Wolmark, Soonmyung Paik, S. Paik, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families

A. Mes-Masson, W. Foulkes, D. Provencher, 2008, Breast Cancer Research and Treatment.

The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40

S. Paik, G. Tang, J. Costantino, 2017, Annals of Surgical Oncology.

The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30

Z. Aziz, A. Robidoux, S. Narod, 2009, Familial Cancer.

The identification of challenges in tissue collection for biomarker studies: the Q-CROC-03 neoadjuvant breast cancer translational trial experience

G. Batist, A. Robidoux, M. Basik, 2017, Modern Pathology.

Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial.

R. Gelber, C. Geyer, N. Wolmark, 2014, The Lancet. Oncology.

Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02.

H. Rockette, C. Redmond, D. Wickerham, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trials.

K. Gelmon, J. Mackey, R. Kerbel, 2012, Cancer treatment reviews.

Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.

M. Dowsett, T. Julian, M. Cheang, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40.

G. Tang, J. Costantino, C. Geyer, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab added to neoadjuvant chemotherapy for breast cancer.

James A Young, Norman Wolmark, Rita S Mehta, 2012, The New England journal of medicine.

Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

T. Julian, D. Wickerham, N. Wolmark, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial.

R. Gelber, C. Geyer, N. Wolmark, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.

J. Costantino, C. Geyer, D. Wickerham, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer

E. Perez, C. Geyer, P. Ward, 2022, Breast Cancer Research and Treatment.

Small-cell carcinoma of the rectum

W. Schürch, A. Robidoux, J. Heppell, 1985, Diseases of the Colon & Rectum.

Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer

M. Beckmann, P. Lønning, K. Blackwell, 2010, Expert review of anticancer therapy.

Intra-arterial infusion chemotherapy in rectal cancer.

A. Robidoux, J. Sylvestre, J. Chalaoui, 1984, Canadian journal of surgery. Journal canadien de chirurgie.

Breast cancer risk and nutrient intake among French Canadians in Montreal: a case-control study

P. Boyle, A. Robidoux, P. Maisonneuve, 1998 .

A prospective pilot study investigating the musculoskeletal pain in postmenopausal breast cancer patients receiving aromatase inhibitor therapy.

J. Turgeon, D. Laperrière, S. Mader, 2011, Current oncology.

Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial.

E. Perez, J. Costantino, C. Geyer, 2012, The Lancet. Oncology.

Out-of-pocket costs in the year after early breast cancer among Canadian women and spouses.

D. Coyle, A. Robidoux, S. Lauzier, 2013, Journal of the National Cancer Institute.

Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study

G. Pond, A. Robidoux, S. Chia, 2014, Breast Cancer Research and Treatment.

Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women

W. Foulkes, A. Robidoux, S. Narod, 2007, Breast Cancer Research.

Prevalence of founder BRCA1 and BRCA2 mutations in unselected French Canadian women with breast cancer

P. Tonin, A. Robidoux, N. Hamel, 2001, Clinical genetics.

NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response

G. Tang, C. Geyer, N. Wolmark, 2020, Clinical Cancer Research.

Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer.

J. Cuzick, A. Buzdar, R. Chlebowski, 2009, Breast.

In the end what matters most? A review of clinical endpoints in advanced breast cancer.

J. Mackey, S. Verma, G. Batist, 2011, The oncologist.

Wage losses in the year after breast cancer: extent and determinants among Canadian women.

D. Coyle, A. Robidoux, S. Lauzier, 2008, Journal of the National Cancer Institute.

Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours

J. Schellens, A. Robidoux, L. Cartee, 2014, Investigational New Drugs.

Couples who get closer after breast cancer: frequency and predictors in a prospective investigation.

A. Robidoux, S. Guay, M. Dorval, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Psychological distress and physical health in the year after diagnosis of DCIS or invasive breast cancer

A. Robidoux, S. Lauzier, E. Maunsell, 2010, Breast Cancer Research and Treatment.

Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9

M. Buyse, N. Wolmark, A. Tan, 2015, Breast Cancer Research and Treatment.

A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer.

A. Buzdar, C. Geyer, N. Wolmark, 2010, Clinical breast cancer.

Adjuvant Chemotherapy for Locoregional Recurrent Breast Cancer

Joseph P. Costantino, Stewart J. Anderson, Norman Wolmark, 2011 .

A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37.

R. Gelber, M. Piccart, J. Costantino, 2008, Clinical breast cancer.

Results of a multicenter randomized trial to evaluate a survivorship care plan for breast cancer survivors.

G. Pond, A. Robidoux, K. Pritchard, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Metastatic axillary lymph node technetium-99m-MIBI imaging in primary breast cancer.

A. Robidoux, R. Taillefer, J. Léveillé, 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Technetium-99m-sestamibi prone scintimammography to detect primary breast cancer and axillary lymph node involvement.

A. Robidoux, R. Taillefer, R. Lambert, 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

The contribution of founder mutations to early‐onset breast cancer in French‐Canadian women

A. Robidoux, F. Rousseau, M. Akbari, 2009, Clinical genetics.

Gemcitabine/epirubicin/paclitaxel as neoadjuvant chemotherapy in locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.

G. Tseng, S. Paik, W. Kim, 2008, Clinical breast cancer.

Validating the content of a brief informational intervention to empower patients and spouses facing breast cancer: perspectives of both couple members

A. Robidoux, S. Guay, S. Lauzier, 2014, Journal of Cancer Survivorship.

Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination

G. Tang, C. Geyer, N. Wolmark, 2019, Breast Cancer Research and Treatment.

Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: 5-year outcomes of NSABP protocol B-41.

S. Paik, G. Tang, J. Costantino, 2016 .

Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer

S. Paik, N. Wolmark, K. Pogue-Geile, 2019, Breast Cancer Research.

NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer

S. Paik, N. Wolmark, K. Pogue-Geile, 2019, Breast Cancer Research.

Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers

O. Olopade, P. Møller, W. Foulkes, 2014, Breast Cancer Research and Treatment.

Intrinsic subtypes of HER2-positive breast cancer and their associations with pathologic complete response (pCR) and outcomes: Findings from NSABP B-41, a randomized neoadjuvant trial.

G. Tang, C. Geyer, N. Wolmark, 2018 .

Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor – Positive Early Breast Cancer

Maggie, Morden., M. Dowsett, 2019 .

Wage losses among spouses of women with nonmetastatic breast cancer

D. Coyle, A. Robidoux, S. Lauzier, 2019, Cancer.

MAF Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice

R. Gomis, N. Wolmark, A. Wolff, 2021, JNCI cancer spectrum.

S2-3: NSABP Protocol B-34: A Clinical Trial Comparing Adjuvant Clodronate vs. Placebo in Early Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Tamoxifen or No Therapy – Final Analysis.

J. Costantino, N. Wolmark, S. Swain, 2011 .

Chemotherapy (CT) for isolated locoregional recurrence (ILRR) of breast cancer in ER-positive (ER+) and ER-negative (ER-) cohorts: Final analysis of the CALOR trial.

R. Gelber, N. Wolmark, J. Nortier, 2017 .

Patterns of confidant use among patients and spouses in the year after breast cancer

A. Robidoux, S. Guay, S. Lauzier, 2009, Journal of cancer survivorship : research and practice.

Canadian initiatives for locally advanced breast cancer research and treatment: inaugural meeting of the Canadian Consortium for LABC.

J. Mackey, M. Brackstone, A. Robidoux, 2011 .

The LISA randomized trial of a weight loss intervention in postmenopausal breast cancer

G. Pond, J. Gralow, A. Robidoux, 2020, npj Breast Cancer.

[Quality of life of patients after restorative surgery for cancer of the rectum].

A. Robidoux, J. Heppell, J. Lasry, 1992, Annales de chirurgie.

Out-of-pocket costs for accessing adjuvant radiotherapy among Canadian women with breast cancer.

D. Coyle, A. Robidoux, S. Lauzier, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Prospective Pilot Study Investigating the Nature, the Onset and the Incidence of Joint Pain in Menopausal, Breast Cancer Patients Receiving Aromatase Inhibitor (AI) Therapy.

J. Turgeon, S. Mader, A. Robidoux, 2009 .

Frequency adaptation for enhanced radiation force amplitude in dynamic elastography

L. Gaboury, A. Robidoux, G. Cloutier, 2015, IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control.

Limitations of Personalized Medicine and Gene Assays for Breast Cancer

A. Robidoux, P. Wong, D. Shédid, 2017, Cureus.

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer

J. Bryant, D. Wickerham, H. Bear, 2023, Journal of Clinical Oncology.

A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors.

C. Redmond, J. Costantino, D. Wickerham, 1989, The New England journal of medicine.

In the end what matters most? A review of clinical endpoints in advanced breast cancer.

J. Mackey, S. Verma, G. Batist, 2011, The oncologist.

Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer

S. Paik, N. Wolmark, K. Pogue-Geile, 2019, Breast Cancer Research.

A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer.

A. Buzdar, C. Geyer, N. Wolmark, 2010, Clinical breast cancer.

A prospective pilot study investigating the musculoskeletal pain in postmenopausal breast cancer patients receiving aromatase inhibitor therapy.

J. Turgeon, D. Laperrière, S. Mader, 2011, Current oncology.

The Added Value of Statistical Modeling of Backscatter Properties in the Management of Breast Lesions at US.

Guy Cloutier, François Destrempes, Boris Chayer, 2015, Radiology.

Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study.

M. Brackstone, L. Gaboury, A. Robidoux, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Circulating tumor DNA (ctDNA) during and after neoadjuvant chemotherapy and prior to surgery is a powerful prognostic factor in triple-negative breast cancer (TNBC).

A. Robidoux, E. Bareke, N. Alirezaie, 2019, Journal of Clinical Oncology.

Wage losses in the year after breast cancer: extent and determinants among Canadian women.

D. Coyle, A. Robidoux, S. Lauzier, 2008, Journal of the National Cancer Institute.

NSABP FB-6: Phase II trial of weekly paclitaxel (WP) and pazopanib following doxorubicin and cyclophosphamide (AC) as neoadjuvant therapy for HER2-negative locally advanced breast cancer (LABC).

M. Buyse, T. Julian, S. Paik, 2012 .

Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41.

S. Paik, G. Tang, J. Costantino, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.